Short-acting beta-2 adrenergic agonists (SABA)
ATC code: R03AC02 (Salbutamol (Albuterol))
Brand names
Ventolin, ProAir
Selective beta-2 adrenergic agonist on bronchial smooth muscle. Relaxes smooth muscle and dilates bronchi via adenylyl cyclase activation and increased cAMP. Onset 5–15 minutes after inhalation, duration 4–6 hours. A reliever, not a controller. Since 2019, SABA monotherapy in asthma is no longer recommended — it is associated with worse control and increased mortality.
First line
First-line reliever for acute bronchospasm of any cause (asthma, COPD, allergic airway edema, exercise). Dose via pMDI: 2 puffs of 100 mcg (total 200 mcg), repeatable in 20 minutes. Via nebulizer in severe exacerbation: 2.5–5 mg in 2.5 mL saline, repeat every 20 minutes for up to 3 doses. Onset 5–15 minutes.
Used in children from the first year of life on clinical grounds. Always via spacer, with a face mask for the youngest.
First line
2024 recommends salbutamol as a rescue bronchodilator in COPD. Maintenance therapy relies on long-acting bronchodilators (LAMA and/or LABA), while SABA is used on demand for episodes of dyspnea.
First line
Per ATS 2013 and 2024, salbutamol 200 mcg taken 15 minutes before exercise is first-line prophylaxis for exercise-induced bronchoconstriction in patients without underlying asthma. In asthma patients, daily prophylactic SABA is not needed — optimize controller ICS therapy. Frequent pre-exercise SABA use leads to tachyphylaxis.
Individual decision
Per 2024, the preferred reliever in adults and adolescents from age 12 across all asthma steps is a fixed combination of low-dose ICS + formoterol (e.g., budesonide/formoterol) rather than salbutamol. SABA monotherapy is associated with increased asthma mortality (Cochrane meta-analysis). SABA use more than twice weekly is a marker of poor control. In children under 5, salbutamol remains the first-line reliever, with ICS added as a controller.
As a reliever only. SABA monotherapy is contraindicated in persistent asthma.
Not recommended
Salbutamol is not mentioned in international guidelines for viral URI without bronchospasm. A 2014 Cochrane review found no benefit in children with acute bronchitis without wheezing. Use in patients without airflow obstruction produces only tachycardia and tremor with no clinical benefit.
Not recommended
In bodybuilding salbutamol is used on rumours of anabolic beta-2 agonist effects. Controlled human studies do not demonstrate clinically meaningful muscle mass gain. Attributed effects are limited to weight loss and metabolic rate increase – not muscle growth. WADA lists beta-2 agonists as prohibited in most contexts. High-dose use carries substantial arrhythmia and sudden-death risk.
Not recommended
In fitness communities salbutamol is sometimes used as a 'clenbuterol replacement' for thermogenic effects and weight loss. This use is dangerous: tachycardia, tremor, hypokalaemia, and arrhythmias at systemic doses, especially combined with other beta-agonists. International obesity guidelines (, ) do not mention salbutamol. Inhaled delivery has minimal systemic bioavailability, so 'weight loss' use requires oral administration or high doses – doubling the risk.
FDA categories were retired in 2015. Inhaled salbutamol is compatible with pregnancy for asthma symptom relief — the risk of untreated asthma to the fetus exceeds the theoretical drug risk.
Compatible with breastfeeding. Systemic bioavailability after inhalation is low, with minimal transfer to milk.
salbutamol (Albuterol) is evaluated for the following indications with varying evidence strength: Acute bronchospasm (evidence tier A), Chronic obstructive pulmonary disease (evidence tier A), Exercise-induced bronchoconstriction (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of salbutamol (Albuterol) (≥ 1 in 100): Hand tremor, Tachycardia, palpitations, Headache, Hypokalemia (with high nebulized doses), Throat irritation, cough after inhalation. See the Safety section for uncommon and serious reactions.
FDA categories were retired in 2015. Inhaled salbutamol is compatible with pregnancy for asthma symptom relief — the risk of untreated asthma to the fetus exceeds the theoretical drug risk.
Compatible with breastfeeding. Systemic bioavailability after inhalation is low, with minimal transfer to milk.
salbutamol (Albuterol) is contraindicated in: Hypersensitivity; Uncorrected severe tachyarrhythmias. Full list in the Safety section.
daily SABA without ICS in asthma raises mortality. Controllers (ICS or ICS + formoterol) are the foundation; SABA is for symptoms only.
there is no physiological dependence. High-frequency use signals poor control of the underlying disease — controller therapy needs optimization.
WADA permits inhaled doses up to 1600 mcg daily with a medical indication. Oral and injectable use is prohibited without a TUE.